BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial UpdateGlobeNewsWire • 02/20/25
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025GlobeNewsWire • 02/13/25
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CMGlobeNewsWire • 02/11/25
Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?Zacks Investment Research • 01/14/25
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.Investors Business Daily • 01/13/25
BridgeBio Announces Commercial Progress, Program Updates, and 2025 MilestonesGlobeNewsWire • 01/13/25
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the marketCNBC • 01/08/25
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewsWire • 12/13/24
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and OncologyGlobeNewsWire • 12/03/24
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart DrugInvestors Business Daily • 11/25/24
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive MarketBenzinga • 11/25/24
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM PatientsGlobeNewsWire • 11/23/24
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM MarketBenzinga • 11/19/24
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 MonthsGlobeNewsWire • 11/18/24
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive DirectorBusiness Wire • 11/18/24
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with AchondroplasiaGlobeNewsWire • 11/18/24
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio ManagementGlobeNewsWire • 11/05/24